文献速递毛发、甲与色素性疾病

双光子显微镜在体评估黄褐斑病理特征及治疗反应

In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy.
PubMed 文献 · JAMA Dermatol · 2025-08-13

该单中心、评估者盲法观察性研究纳入60例黄褐斑患者,采用双光子显微镜(TPM)在体检测皮损及周围区域的病理特征,并监测2%氢醌乳膏治疗12周后的反应。研究发现黄褐斑皮损各表皮层黑素增加、活性黑素细胞增多等特征,治疗后TPM显示黑素含量和活性黑素细胞显著下降。

要点

  • TPM可在体无创检测黄褐斑黑素分布及黑素细胞活性等病理特征。
  • 2%氢醌治疗12周后mMASI和皮肤镜评分显著下降,TPM显示黑素减少。
  • TPM或可用于黄褐斑疗效的细胞级评估。

核心结论

  • TPM可在体检测黄褐斑病理特征并评估细胞水平的治疗反应。

研究设计与样本

  • 单中心、评估者盲法观察性研究,纳入60例临床诊断黄褐斑患者(57女,3男;中位年龄39.5岁)。

主要发现

  • 与周围皮肤相比,黄褐斑皮损各表皮层黑素增加(角质层中位数1 vs 0;颗粒层1 vs 0;浅棘层2 vs 1;深棘层3 vs 2;基底层3 vs 4 vs 2),呈斑驳分布,且差异均有统计学意义(P<.001)。
  • 皮损区存活表皮厚度降低(中位数43.5 µm vs 48.0 µm;中位差-4.50;95%CI -6.58至-3.70),网嵴变平(94.17% vs 69.17%),真皮表皮交界处活性黑素细胞增多(中位数2 vs 1;中位差1;95%CI 0.70-1.00)和悬垂黑素细胞增多,日光性弹性纤维变性更严重(P<.001)。
  • 53例(88.3%)完成12周2%氢醌治疗,平均mMASI评分下降29.81%(95%CI 22.75%-36.72%;P<.001),皮肤镜色素评分下降36.16%(95%CI 30.07%-42.25%;P<.001)。
  • 治疗后TPM显示各表皮层黑素含量显著降低(角质层中位数1 vs 1;颗粒层2 vs 1;浅棘层2 vs 1;深棘层3 vs 2;基底层3 vs 2;均P<.001),DEJ处活性黑素细胞减少(中位数2 vs 1;P<.001),但悬垂黑素细胞和日光性弹性纤维变性无统计学变化。

临床怎么用

  • TPM可作为黄褐斑无创病理诊断和疗效监测的潜在工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Melasma, a complex and clinically challenging facial pigmentary disorder, lacks in vivo pathologic tools for definitive diagnosis and accurate efficacy assessment. OBJECTIVE: To use 2-photon microscopy (TPM) for noninvasive pathologic detection of melasma and therapeutic response monitoring to hydroquinone cream, 2%. DESIGN, SETTING, AND PARTICIPANTS: This single-center, evaluator-blinded, observational study consisting of 2 sequential phases was conducted at the Dermatology Outpatient Clinic of China-Japan Friendship Hospital from January to September 2024. The study population included patients aged 18 to 60 years with clinically diagnosed melasma who were not treated for the condition in the past 3 months, without other facial dermatoses, free of malignant disease history, and not pregnant and nonlactating. EXPOSURE AND INTERVENTION: In the first phase, participants underwent noninvasive TPM 3-dimensional imaging of lesional and perilesional areas. In the second phase, all participants were treated with hydroquinone cream, 2% twice daily for 12 weeks. MAIN OUTCOMES AND MEASURES: In phase 1, the main outcome was TPM pathologic features. In phase 2, the main measures were modified Melasma Area and Severity Index (mMASI) scores, dermoscopic scores, and TPM indexes at baseline and weeks 4, 8, and 12. RESULTS: The TPM images of 120 lesional and perilesional areas from 60 patients (57 female individuals, 3 male individuals; median [IQR] age, 39.5 [37.0-45.8] years) were analyzed. Compared with the perilesions, melasma lesions showed increased melanin across all epidermal layers (stratum corneum: median [IQR], 1 [0-2] vs 0 [0-0]; stratum granulosum: median [IQR], 1 [1-2] vs 0 [0-0]; superficial stratum spinosum: median [IQR], 2 [1-3] vs 1 [1-1]; deep stratum spinosum: median [IQR], 3 [2-3] vs 2 [1-2]; stratum basale: median [IQR], 3 [3-4] vs 2 [2-3]) in a mottled distribution, reduced viable epidermal thickness (median [IQR], 43.5 [39.0-48.0] µm vs 48.0 [43.9-54.0] µm; median difference, -4.50; 95% CI, -6.58 to -3.70), flattened rete ridges (94.17%; 95% CI, 88.45%-97.15% vs 69.17%; 95% CI, 60.42%-76.73%), increased activated (median [IQR], 2 [1-2] vs 1 [1-1]; median difference, 1; 95% CI, 0.70-1.00) and pendulous (median [IQR], 0 [0-1] vs 0 [0-0]) melanocytes at the dermal-epidermal junction (DEJ), and more severe solar elastosis (median [IQR], 2 [2-3] vs 2 [1-2]) (all P<.001). Among them, 53 patients (88.3%) completed 12 weeks of hydroquinone treatment, the mean mMASI scores and dermoscopic pigmentary scores decreased by 29.81% (95% CI, 22.75%-36.72%; P < .001) and 36.16% (95% CI, 30.07%-42.25%; P < .001), respectively, after treatment. TPM showed significant decreases in melanin content of each epidermal layer (stratum corneum: median [IQR], 1 [1-2] vs 1 [0-1]; stratum granulosum: median [IQR], 2 [1-2] vs 1 [0-1]; superficial stratum spinosum: median [IQR], 2 [2-3] vs 1 [1-2]; deep stratum spinosum: median [IQR], 3 [3-3] vs 2 [2-3]; and stratum basale: median [IQR], 3 [3-4] vs 2 [2-3]; all P < .001) and activated melanocytes at the DEJ (median [IQR], 2 [2-2] vs 1 [1-2]; P < .001) after treatment, but no statistical changes in pendulous melanocytes or solar elastosis during treatment. CONCLUSIONS AND RELEVANCE: This observational study found that TPM may offer a new paradigm in pigmentary disorder management by enabling in vivo detection of pathologic features and assessment of cellular-level treatment responses.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Ning X, Yang J, Ouyang H, et al. In Vivo Evaluation of Melasma Pathologic Features and Treatment Response by 2-Photon Microscopy. JAMA Dermatol. 2025. PMID: 40802269. doi:10.1001/jamadermatol.2025.2790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。